Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Abstract Background Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV1) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in prior phase 3 trials. We evaluated t...

Full description

Bibliographic Details
Main Authors: James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Glenn D. Crater
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Pulmonary Medicine
Subjects:
COPD
Efficacy
Long-acting muscarinic antagonist
Nebulized therapy
Revefenacin
Online Access:http://link.springer.com/article/10.1186/s12890-020-1156-4

Internet

http://link.springer.com/article/10.1186/s12890-020-1156-4

Similar Items